Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed)
About
The purpose of the notice of funding opportunity (NOFO) is to solicit applications for a Coccidioidomycosis Collaborative Research Centers (CCRC) program. This new initiative will establish highly collaborative, multi-disciplinary, research teams to conduct translational and clinical research to support the development of a Valley fever vaccine as outlined in NIAID's Strategic Plan for Research to Develop a Valley fever Vaccine.
The Coccidioidomycosis Collaborative Research Centers (CCRC) program is a federally funded initiative designed for research institutions and organizations seeking to advance Valley fever vaccine development. This grant supports highly collaborative, multi-disciplinary research teams conducting translational and clinical research aligned with NIAID's Strategic Plan for Valley fever vaccine research. Eligible U.S.-based organizations can receive funding up to $1,200,000 to establish centers that bring together diverse expertise in infectious disease, immunology, vaccine development, and related fields. Researchers and institutional leaders should apply if their organization can demonstrate capacity to lead collaborative teams focused on moving Valley fever vaccine candidates toward clinical application. This program specifically excludes clinical trials, making it ideal for organizations in preclinical and translational research phases. The deadline for submission is July 9, 2026. This is a significant opportunity for research institutions committed to addressing Valley fever, a serious fungal infection affecting thousands in endemic regions. Organizations must be domestic U.S. entities to be eligible, though international collaborations with foreign components are permitted. Applicants should review the complete Notice of Funding Opportunity (NOFO) for detailed eligibility requirements and application procedures on the official NIH/NIAID website.
Funding Facts
● Applications openDeadline
July 9, 2026
Award Amount
Up to $1.2M
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
Up to $1.2M
Deadline
2026-07-09
Grant Type
federal
Application Cycle
Annual - Deadline July 9, 2026
Best For
U.S. research institutions, universities, and organizations with multi-disciplinary teams focused on Valley fever vaccine development and translational research
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Frequently Asked Questions
Who is eligible for Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed)?
Eligible applicants are domestic U.S. organizations and research institutions. Foreign organizations and non-U.S. entities cannot apply as primary applicants, though foreign components within U.S. organizations are permitted as collaborative elements. For comprehensive eligibility details, including specific organizational types, institutional requirements, and qualifications, refer to Section III of the official Notice of Funding Opportunity (NOFO) on the NIH website.
How much funding does Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed) provide?
The funding range for this program is up to $1,200,000. The specific amount awarded to individual projects may vary based on the scope of research, institutional capacity, and reviewer recommendations. Applicants should consult the official NOFO for detailed budget guidelines and cost-sharing requirements.
How do I apply for Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed)?
Applications are submitted through the NIH grants portal according to the procedures outlined in the Notice of Funding Opportunity. The deadline for submission is July 9, 2026. Applicants must prepare a comprehensive application including research plans, organizational capacity documentation, letters of collaboration from team members, and budget justifications. Visit the official NIH/NIAID website for the complete NOFO, application instructions, and submission portal access.
What can Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed) funding be used for?
Funding supports translational and clinical research aimed at developing a Valley fever vaccine. Acceptable uses include personnel costs, equipment, supplies, and direct research expenses for multi-disciplinary teams. However, this program specifically does not support clinical trials. Funding is designed for collaborative research centers focused on moving vaccine development forward through preclinical and early translational research phases aligned with NIAID's Valley fever vaccine research strategy.
Last updated: July 5, 2026